NCT02447055

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma: a Pilot Feasibility Study Using a Novel Protocol

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to develop a novel platform for allo-SCT in multiple myeloma (MM) with the idea of maximizing anti-myeloma effect with conditioning and minimizing GvHD (graft versus host disease). Specifically, the investigators will use the Flu/Mel (fludarabine and melphalan) regimen. For GvHD prophylaxis, the investigators use the Hopkins PT-Cy (post-transplant cyclophosphamide) platform with the novelty of adding tocilizumab as both an anti-myeloma therapy and as a method to reduce GvHD. IL-6 has an important role in promoting the growth of myeloma cells and progression of disease.

Conditions

• Multiple Myeloma
• Myeloma-Multiple

Interventions

Type	Name	Description
BIOLOGICAL	Tocilizumab
DRUG	Melphalan
DRUG	Fludarabine
DRUG	Cyclophosphamide
DRUG	Tacrolimus
DRUG	Mycophenolate mofetil
DRUG	Filgrastim

Timeline

• Start date: 2015-12-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2015-05-18
• Last updated: 2016-07-12